Recombinant human HER2 monoclonal antibody - Anhui Anke Biotechnology

Drug Profile

Recombinant human HER2 monoclonal antibody - Anhui Anke Biotechnology

Latest Information Update: 22 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Anhui Anke Biotechnology
  • Developer Anhui Anke Biotechnology; Peking University People's Hospital
  • Class Monoclonal antibodies
  • Mechanism of Action ERBB 2 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Breast cancer

Most Recent Events

  • 08 Apr 2016 Phase-I clinical trials in Breast cancer (In volunteers) in China (unspecified route) (ChiCTR-IIR16009808)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top